0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas

Authors

Patients affected by lymphomas relapsing after autografting or with refractory disease are often candidates for reduced-intensity conditioning (RIC) regimens followed by allogeneic stem cell transplantation (SCT). All the published series reported a 2 year progression free-survival of 60%, 40% and 30% in indolent, aggressive and Hodgkin’s Lymphoma (HL), respectively. However, the long-term efficacy and toxicity of this strategy is still unknown. We report herein the long-term results of a prospective multicenter phase II trial at median follow-up of 5 years. A total of 194 relapsed/ refractory lymphomas received the same RIC regimen (thiotepa, cyclophosphamide and fludarabine) followed by allo-SCT from matched sibling donors. Histologies were non-Hodgkin’s lymphomas (NHL) [indolent (LG-NHL, n=68), including follicular lymphoma (FL, n=29), chronic lymphocytic leukemia (CLL, n=35), other (n=4); aggressive (HG-NHL, n=87), including B-cell phenotype (n=43); T-cell phenotype (n=28), mantle cell lymphoma (MCL, n=16)] and Hodgkin’s lymphoma (HL, n=39); 133 (68%) of 194 patients (pts) had chemosensitive disease and 100 (52%) of 194 failed a previous autologous SCT. Median follow-up was 60 months (range, 15-113). At last follow-up, 116 pts are alive (59%) and 78 died from any cause [n=47 for disease progression, n= 30 for non-relapse mortality (NRM), n=1 not assessable]. The 5-year overall survival (OS) and progression-free survival (PFS) were 62% and 70% for LG-NHL, 61% and 59% for HG-NHL, and 42% and 19% for HL, respectively. The median time to relapse was 7 (range, 2- 30), 4.5 (range, 1.6-33), and 5.5 (range, 0.4-42) months for LGNHL, HG-NHL, and HL respectively. Pts with chemosensitive disease at allo-SCT had a 5-year OS and PFS of 69% and 61%, while those with refractory disease had a 5-year OS and PFS of 35% and 45%, respectively.

Supporting Agencies

Novartis

How to Cite

Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F., Miceli, R., Matteucci, P., Scimè, R., Narni, F., Dalto, S., Carniti, C., Bacigalupo, A., Bonifazi, F., Olivieri, A., & Tarella, C. (2009). Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.564